Core Viewpoint - Guangkang Biochemical has seen a significant stock price increase of 68% over five trading days, attributed to the rising trend in innovative drug concept stocks, leading to major shareholders planning to reduce their holdings [2][3][4]. Shareholder Reduction Plans - Major shareholders, including Qiongcheng Ruihong Kaiyin No. 1 Equity Investment Fund, plan to reduce their holdings by up to 222,000 shares, representing 3% of the total share capital, within three months after the announcement [3][4]. - Additional shareholders collectively holding 355,000 shares, accounting for 4.7973% of the total share capital, are also involved in the reduction [3][4]. Company Overview - Guangkang Biochemical specializes in the research, production, and sales of pesticide raw materials, intermediates, and formulations, established in 2003, and is a significant player in Guangdong Province [4]. - The company went public on the ChiNext board on June 27, 2023, and this reduction marks the first instance of shareholder selling post-IPO lock-up expiration [4]. Financial Performance - In 2023, Guangkang Biochemical's revenue declined by 25%, with net profit and non-recurring net profit dropping by 68% and 73%, respectively [6]. - Although revenue showed recovery in 2024, non-recurring net profit continued to decline by 11.45% [6]. - In Q1 2025, both net profit and non-recurring net profit fell by approximately 3% and 9.6%, respectively [6]. Shareholding and Pledge Situation - The major shareholder and actual controller, Cai Danqun, is unable to reduce shares due to a 36-month lock-up period but has pledged shares for financing, with the pledge subject to high-interest rates from guarantee companies [8][9].
五天暴涨68%，群起减持！